Therapeutic drug monitoring of lopinavir/ritonavir given alone or with a non-nucleoside reverse transcriptase inhibitor

British Journal of Clinical Pharmacology

Volumn 57, Issue 4, 2004, Pages 436-440

  Solas, Caroline ^a,e   Poizot Martin, Isabelle ^a   Drogoul, Marie Pierre ^a   Ravaux, Isabelle ^a   Dhiver, Catherine ^a   Lafeuillade, Alain ^b   Allegre, Thierry ^c   Mokhtari, Malika ^a   Moreau, Jacques ^a   Lepeu, Gérard ^d   Petit, Nathalie ^a   Durand, Alain ^a   Lacarelle, Bruno ^a  

^a AP HM Timone ^*  (France)

^b Hopital Chalucet Toulon   (France)

^c General Hospital of Aix   (France)

^d CENTRE HOSPITALIER D AVIGNON   (France)

^e TIMONE HOSPITAL   (France)

Author keywords

Drug interaction; Pharmacokinetic; Protease inhibitors

Indexed keywords

EFAVIRENZ; LOPINAVIR PLUS RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADOLESCENT; ADULT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG MONITORING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT;

ADOLESCENT; ADULT; DRUG EVALUATION; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PYRIMIDINONES; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR;

EID: 11144357775     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2003.02020.x     Document Type: Article

References (21)

1. Sham H, Kempf D, Molla A et al. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob Agents Chemother 1998; 42: 3218-24.
2. Murphy RL, Brun S, Hicks C et al. ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-weeks results. AIDS 2001; 15: F1-F9.
3. Kaletra (lopinavir/ritonavir) capsules. US Prescribing information. Abbott Park, IL: Abbott Laboratories, 2000.
4. Hsu A, Granneman GR, Kempf DJ et al. The Ctrough inhibitory quotient predicts virologic response to ABT-378/ritonavir (ABT378/R) therapy in treatment-experienced patients. 5th International Congress on Drug Therapy in HIV Infection, Glasgow. Abstract PL9.4, 2000.
5. Acosta EP, Henry K, Baken L, Page LM, Fletcher CV. Indinavir concentrations and antiviral effect. Pharmacotherapy 1999; 19: 708-12.
6. Acosta EP, Havlir DV, Richman DD et al. Pharmacodynamics (PD) of indinavir (IDV) in protease-naive HIV-infected patients receiving ZDV and 3TC. 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA. Abstract 455, 2000.
7. Dieleman JP, Gyssens IC, Van der Ende ME, de Marie S, Burger DM. Urologic complaints in relation to indinavir plasma concentrations in HIV-infected patients. AIDS 1999; 13: 473-8.
8. Dumon C, Solas C, Thuret I et al. Relationship between efficacy, tolerance and plasma drug concentration of ritonavir in children with advanced HIV infection. Ther Drug Monit 2000; 22: 402-8.
9. Gatti G, Di Biagio A, Casazza R et al. The relationship between ritonavir plasma levels and side-effects: implications for therapeutic drug monitoring. AIDS 1999; 13: 2083-9.
10. Gieschke R, Fotteler B, Buss N, Steimer J. Relationships between exposure to saquinavir monotherapy and antiviral response in HIV-positive patients. Clin Pharmacokinet 1999; 37: 75-86.
11. Sadler BM, Gillotin C, Lou Y, Stein DS. Pharmacokinetic and pharmacodynamic study of the human immunodeficiency virus protease inhibitor amprenavir after multiple oral dosing. Antimicrob Agents Chemother 2001; 45: 30-7.
12. Schapiro JM, Winters MA, Stewart F et al. The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients. Ann Intern Med 1996; 124: 1039-50.
13. Recommandations du Groupe d'Experts. Rapport 2000 sous la direction du Pr JF Delfraissy. Prise en charge thérapeutique des personnes infectés par le VIH. Paris: Medecine-Sciences, Flammarion, 2000.
14. Burger DM, Hugen PWH, Droste J et al. Therapeutic drug monitoring (TDM) of indinavir (IDV) and of nelfinavir (NFV) in treatment-naive patients improves therapeutic outcome after 1 year: results from ATHENA. 2nd International Workshop on Clinical Pharmacology of HIV Therapy, Noordwijk. Abstract 6.2, 2001.
15. Burger DM, Hugen PWH, Aamoutse RE et al. Treatment failure of nelfinavir-containing triple therapy can largely be explained by low nelfinavir plasma concentrations. Ther Drug Monit 2003; 25: 73-80.
16. Bertz R, Hsu A, Lam W et al. Pharmacokinetic interactions between lopinavir/ritonavir (ABT-378/r) and other non-HIV drugs. 5th International Congress on Drug Therapy in HIV Infection, Glasgow. Abstract P291, 2000.
17. Rockstroh J, Brun S, Sylte J et al. ABT-378/ritonavir (ABT-378/r) and efavirenz one year safety/efficacy evaluation in multiple Pl experienced patients. 5th International Congress on Drug Therapy in HIV, Glasgow. Abstract P43, 2000.
18. Hsu A, Bertz R, Renz C et al. Assessment of pharmacokinetic interactions between Kaletra™ (lopinavir/ritonavir or ABT-378/r) and nevirapine in pediatric subjects. 5th International Congress on Drug Therapy in HIV, Glasgow. Abstract 440, 2000.
19. Jayewardene AL, Zhu F, Aweeka FT, Gambertoglio JG. Simple high-performance liquid chromatographic determination of the protease inhibitor indinavir in human plasma. J Chromatogr B 1998; 707: 203-11.
20. Solas C, Basso S, Poizot-Martin I et al. High indinavir Ctrough is associated with higher toxicity in patients on indinavir-ritonavir 800/100 mg twice-daily regimen. J Acquir Immune Defic Syndr 2002; 29: 374-7.
21. Cameron DW, Japour AJ, Xu Y et al. Ritonavir and saquinavir combination therapy for the treatment of HIV infection. AIDS 1999; 13: 213-24.